European Medicines Agency decision
P/0058/2019

of 26 February 2019
on the agreement of a paediatric investigation plan and on the granting of a deferral for pretomanid (EMEA-002115-PIP01-17) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.
European Medicines Agency decision
P/0058/2019

of 26 February 2019

on the agreement of a paediatric investigation plan and on the granting of a deferral for pretomanid (EMEA-002115-PIP01-17) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,


Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Global Alliance for TB Drug Development on 22 January 2018 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 1 February 2019, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

Has adopted this decision:

**Article 1**

A paediatric investigation plan for pretomanid, tablet, dispersible tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

**Article 2**

A deferral for pretomanid, tablet, dispersible tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 3**

This decision is addressed to Global Alliance for TB Drug Development, 40 Wall Street, NY 10005 - New York, United States.
Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral
EMEA-002115-PIP01-17

Scope of the application

Active substance(s):
Pretomanid

Condition(s):
Treatment of multi-drug-resistant tuberculosis

Pharmaceutical form(s):
Tablet
Dispersible tablet

Route(s) of administration:
Oral use

Name/corporate name of the PIP applicant:
Global Alliance for TB Drug Development

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Global Alliance for TB Drug Development submitted for agreement to the European Medicines Agency on 22 January 2018 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 27 February 2018.

Supplementary information was provided by the applicant on 29 October 2018. The applicant proposed modifications to the paediatric investigation plan.
Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
   - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subsets of the paediatric population and condition covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.
Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)
1. Waiver

Not applicable.

2. Paediatric investigation plan

2.1. Condition:

Treatment of multi-drug-resistant tuberculosis

2.1.1. Indication(s) targeted by the PIP

Pretomanid is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

- Tablet
- Dispersible tablet

2.1.4. Measures

<table>
<thead>
<tr>
<th>Area</th>
<th>Number of measures</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quality-related studies</td>
<td>1</td>
<td>Study 1 Development of dispersible tablet formulation.</td>
</tr>
<tr>
<td>Non-clinical studies</td>
<td>1</td>
<td>Study 2 Juvenile toxicity study in rats.</td>
</tr>
</tbody>
</table>
| Clinical studies          | 3                  | **Study 3** An open-label, randomized, 4-period crossover study in 2 panels of healthy, adult subjects to assess the relative bioavailability, food effect, and dose dependence of the formulations of pretomanid.  
**Study 4** An open-label, single-dose study to assess the pharmacokinetics, safety and tolerability of pretomanid in paediatric patients with multidrug-resistant or extensively drug-resistant tuberculosis (MDR-TB or XDR-TB). |
### Study 5

An open-label, multicenter study to evaluate the pharmacokinetics, safety, tolerability and anti-mycobacterial activity of pretomanid in combination with bedaquiline and linezolid (B-Pa-L) for the treatment of paediatric patients with confirmed or probable pulmonary pre-multidrug-resistant or extensively drug-resistant tuberculosis (XDR/XDR-TB), or those who have failed or are intolerant to treatment for multidrug-resistant tuberculosis (MDR-TB).

### Study 6

Population pharmacokinetic (PK) modelling and simulation study in paediatric patients with pulmonary (with or without extrapulmonary) infection of either extensively drug-resistant tuberculosis (XDR-TB), pre-XDR-TB or treatment intolerant or non-responsive multi-drug resistant tuberculosis (MDR-TB).

### Study 7

Extrapolation study of the clinical efficacy and safety data for pretomanid in combination with bedaquiline and linezolid (B-Pa-L regimen) from adult patients to paediatrics patients with pulmonary (with or without extrapulmonary) infection of either extensively drug-resistant tuberculosis (XDR-TB), pre-XDR-TB or treatment intolerant or non-responsive multi-drug resistant tuberculosis (MDR-TB).

### 3. Follow-up, completion and deferral of PIP

| Concerns on potential long term safety/efficacy issues in relation to paediatric use: | Yes |
| Date of completion of the paediatric investigation plan: | By June 2025 |
| Deferral for one or more measures contained in the paediatric investigation plan: | Yes |